微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > chronic constipation
chronic constipation

消化

关键词消化 临床研究术语 便秘

词汇介绍

拓展阅读

解析

Chronic 英 /ˈkrɒnɪk/  美 /ˈkrɑːnɪk/ 

释义   adj.慢性的;长期的;习惯性的

例句   In some people, constipation is chronic and can last 12 weeks or more. 有些人的便秘是慢性的,可以持续12周或者更长。

 

constipation 英 /ˌkɒnstɪˈpeɪʃn/   美 /ˌkɑːnstɪˈpeɪʃn/ 

释义   n. [临床] 便秘;受限制

例句   Do you have trouble with constipation. 你有便秘的困扰吗?


概述

便秘是指粪便干结、排便困难或不尽感、完全排空粪便的次数明显减少,如同时存在>2种症状,可诊断为症状性便秘。慢性便秘是指病程至少6个月的便秘。 诱因1)饮食习惯和饮食结构:摄入食物或饮水量过少、饮食精细、缺乏纤维素、长期高脂饮食。2)药物因素:部分抗抑郁药、抗癫痫药、抗精神病药、抗震颤麻痹药、抗组胺药、抗胆碱类解痉药、钙拮抗剂、利尿剂、单胺氧化酶抑制剂、阿片类药物、拟交感神经药、神经节阻滞剂、含铝或钙的抗酸药、铋剂、钙剂、铁剂、止泻药、非甾体抗炎药、某些抗菌药物,以及滥用泻药。3)其

Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study复制标题

普鲁卡必利治疗慢性便秘患者的心血管安全性: 一项基于多国人群的队列研究

发表时间:2019-05-27

影响因子:3.5

作者: Alicia Gilsenan

期刊:Drug Safety

Chronic constipation is a common and often debilitating medical problem, with an impact on quality of life. The 5-hydroxytryptamine (serotonin) receptor type 4 (5-HT4) receptor agonists have the potential to treat disorders of gastrointestinal motility, including delayed gastric emptying and colonic dysmotility. The frst-generation 5-HT4 receptor agonists cisapride and tegaserod were with drawn from the US market because of serious concerns about associated cardiovascular risk, arrythmias thought to be associated with QTc prolongation with cisapride, and ischemic events of uncertain origin with tegaserod. Prucalopride, a selective 5-HT4 agonist with high affinity and selectivity for the 5-HT4 receptors, has been licensed in the European Union since 2009 for adult women and since 2015 for adult men for the treatment of chronic constipation and is currently approved in 82 countries. No signal for an increased risk of adverse cardiovascular events or QTc prolongation has been observed for prucalopride during non-clinical and clinical cardiovascular investigations or as a result of safety monitoring.

译文

慢性便秘是一种常见且经常使人衰弱的医学问题,会影响生活质量。 5-羟色胺(5-羟色胺)4型受体(5-HT4)受体激动剂具有治疗胃肠道蠕动疾病的潜力,包括延迟的胃排空和结肠运动障碍。第一代5-HT 4受体激动剂西沙必利和替加色罗是从美国市场撤出的,原因是人们对相关的心血管风险存在严重担忧,心律失常与西沙必利的QTc延长有关,以及替加色罗的起源不确定的局部缺血事件。 Prucalopride是一种对5-HT4受体具有高亲和力和选择性的选择性5-HT4激动剂,自2009年以来已在欧盟获得许可,用于成年女性,自2015年以来已获得成年男性的许可,用于治疗慢性便秘,目前已获82国家。在非临床和临床心血管研究或安全性监测的结果中,未观察到普卡洛必利增加不良心血管事件或QTc延长风险的信号。